Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
04:20:28 EDT Fri 03 May 2024
Enter Symbol
or Name
USA
CA



News for U:CSLLY from 2023-05-04 to 2024-05-03 - 35 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-02 09:30U:CSLLYNews ReleaseRecently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three Seasons
2024-04-30 12:19U:CSLLYNews ReleaseMark Cuban Foundation and CSL Bring AI Bootcamp to Philadelphia Teens
2024-04-30 09:01U:CSLLYNews ReleaseARS Pharmaceuticals Submits Response for neffy(TM) (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
2024-04-24 07:05U:CSLLYNews ReleaseTravere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI(TM) (sparsentan) for the treatment of IgA Nephropathy
2024-04-24 03:00U:CSLLYNews ReleaseCSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI(TM) (sparsentan) for the treatment of IgA Nephropathy
2024-03-19 07:00U:CSLLYNews ReleaseFerinject(TM) approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
2024-03-19 07:00U:CSLLYNews ReleaseFerinject(TM) approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
2024-03-06 09:00U:CSLLYNews ReleaseCSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season
2024-02-23 07:06U:CSLLYNews ReleaseTravere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
2024-02-12 22:54U:CSLLYNews ReleaseHalf year reported NPATA US$2 billion ‚ ¹, ‚ ² Up 13% at constant currency ‚ ³
2024-02-11 17:47U:CSLLYNews ReleaseCSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human])
2024-02-05 08:30U:CSLLYNews ReleaseNew COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
2024-02-05 08:30U:CSLLYNews ReleaseNew COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
2024-01-16 08:00U:CSLLYNews ReleaseHarris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options
2024-01-03 08:00U:CSLLYNews ReleaseCSL Behring Announces Availability of Hizentra ‚ ® (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe
2023-12-21 08:00U:CSLLYNews ReleaseCSL and Arcturus Therapeutics ¢ € ™ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
2023-12-21 08:00U:CSLLYNews ReleaseCSL Seqirus Commends the National Advisory Committee on Immunization for Preferential Recommendation of Enhanced Influenza Vaccines for Adults 65 and Older
2023-12-21 08:00U:CSLLYNews ReleaseCSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
2023-12-14 14:47U:CSLLYNews ReleaseCSL's Garadacimab, a First-in-Class Factor XIIa Inhibitor, Receives FDA and EMA Filing Acceptance
2023-12-11 19:30U:CSLLYNews ReleaseCSL Behring's HEMGENIX ‚ ® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B
2023-11-28 08:05U:CSLLYNews ReleaseJapan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults
2023-11-28 08:00U:CSLLYNews ReleaseJapan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics ¢ € ™ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults
2023-11-24 02:00U:CSLLYNews ReleaseIron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment
2023-10-27 10:00U:CSLLYNews ReleaseCSL and uniQure Win 2023 Prix Galien USA Award
2023-10-26 14:14U:CSLLYNews ReleaseHealth Canada Authorizes CSL's HEMGENIX ® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia B
2023-10-11 08:30U:CSLLYNews ReleaseNew Data Presented at IDWeek 2023 Demonstrates Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines
2023-09-19 04:50U:CSLLYNews ReleaseCSL Seqirus Presents Real-World Evidence at ESWI Demonstrating the Impact of Influenza Vaccination Campaigns to Help Protect People and Healthcare Systems
2023-08-28 08:30U:CSLLYNews ReleaseCSL Seqirus Announces Third U.S. Government Award in Relation to Influenza A(H5N8) Candidate Vaccine
2023-08-28 07:00U:CSLLYNews ReleaseFerinject ‚ ® granted upgraded recommendations in 2023 ESC heart failure guidelines
2023-08-17 07:08U:CSLLYNews ReleaseCSL Appoints Jeffrey Ball as First Chief Sustainability Officer
2023-07-17 08:30U:CSLLYNews ReleaseCSL Seqirus Begins Shipping Portfolio of Innovative Influenza Vaccines for the 2023/24 U.S. Season
2023-06-20 07:00U:CSLLYNews ReleaseCSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX ‚ ® (etranacogene dezaparvovec-drlb) for Hemophilia B
2023-06-05 09:00U:CSLLYNews ReleaseInjectafer ‚ ® approved in the U.S. for the treatment of iron deficiency in patients with heart failure
2023-05-18 02:00U:CSLLYNews ReleaseKapruvia ‚ ® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
2023-05-18 02:00U:CSLLYNews ReleaseKapruvia ‚ ® (difelikefalin) recommended by England ¢ € ™s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus